29 research outputs found

    The relationships between work intensity, workaholism, burnout, and self‐reported musculoskeletal complaints

    No full text
    Technological advances within the work environment have dynamically changed the tools with which work is done and the methods applied for performing it, with a large amount of modern work being fast‐paced and sedentary in nature, that is, being done seated in front of a computer screen. This study investigated the relationship between work intensity, workaholism, burnout, and musculoskeletal complaints (MSCs). The results of this study could assist organizations in gaining a clearer understanding of how each of these constructs influences the other, promoting a healthier, and ultimately more productive workforce. A cross‐sectional research design was adopted and implemented by means of a survey amongst office employees within a large engineering services organization (n = 398). Structural equation modeling methods were applied to analyze the data. The results revealed that work intensity was positively related to workaholism and that workaholism was, in turn, also positively related to employees’ burnout and MSCs. Finally, burnout was also shown to be significantly related to MSCs. Awareness of these phenomena and the promotion of effort recovery is important to obviate the effects on employee health and well‐being in the long term

    Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study

    No full text
    Abstract Background Treatment with tamoxifen or chemotherapy reduces the risk of contralateral breast cancer (CBC). However, it is uncertain how long the protection lasts and whether the protective effect is modified by patient, tumor, or treatment characteristics. Methods The population-based WECARE Study included 1521 cases with CBC and 2212 age- and year of first diagnosis-matched controls with unilateral breast cancer recruited during two phases in the USA, Canada, and Denmark. Women were diagnosed with a first breast cancer before age 55 years during 1985–2008. Abstraction of medical records provided detailed treatment information, while information on risk factors was obtained during telephone interviews. Risk ratios (RRs) and 95 % confidence intervals (CIs) for CBC were obtained from multivariable conditional logistic regression models. Results Compared with never users of tamoxifen, the RR of CBC was lower for current users of tamoxifen (RR = 0.73; 95 % CI = 0.55–0.97) and for past users within 3 years of last use (RR = 0.73; 95 % CI = 0.53–1.00). There was no evidence of an increased risk of estrogen receptor-negative CBC associated with ever use of tamoxifen or use for 4.5 or more years. Use of chemotherapy (ever versus never use) was associated with a significantly reduced RR of developing CBC 1–4 years (RR = 0.59; 95 % CI = 0.45–0.77) and 5–9 years (RR = 0.73; 95 % CI = 0.56–0.95) after first breast cancer diagnosis. RRs of CBC associated with tamoxifen or with chemotherapy use were independent of age, family history of breast cancer, body mass index and tumor characteristics of the first breast cancer with the exception that the RR of CBC was lower for lobular histology compared with other histologies. Conclusion Our findings are consistent with previous studies showing that treatment with tamoxifen or chemotherapy is associated with a lower risk of CBC although the risk reduction appears to last for a limited time period after treatment is completed
    corecore